Patients with BRAF V600–mutated stage III melanoma received 1 year of adjuvant dabrafenib plus trametinib or placebo. After more than 8 years, the risk of death was 20% lower with treatment, but the benefit was not significant.
The New England Journal of Medicine: Search Results in Hematology/Oncology
